Compare WWW & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WWW | SDGR |
|---|---|---|
| Founded | 1883 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 856.7M |
| IPO Year | 2001 | 2020 |
| Metric | WWW | SDGR |
|---|---|---|
| Price | $17.71 | $13.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $24.88 | $24.33 |
| AVG Volume (30 Days) | 1.3M | ★ 1.6M |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | ★ 96.55 | 45.14 |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $1,874,300,000.00 | $255,869,000.00 |
| Revenue This Year | $5.37 | $6.11 |
| Revenue Next Year | $5.06 | $7.69 |
| P/E Ratio | $15.39 | ★ N/A |
| Revenue Growth | 6.80 | ★ 23.29 |
| 52 Week Low | $9.58 | $11.11 |
| 52 Week High | $32.80 | $27.63 |
| Indicator | WWW | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 50.36 |
| Support Level | $16.82 | $11.11 |
| Resistance Level | $19.44 | $19.51 |
| Average True Range (ATR) | 0.98 | 0.70 |
| MACD | -0.03 | 0.31 |
| Stochastic Oscillator | 17.52 | 92.22 |
Wolverine World Wide Inc is engaged in designing, manufacturing, sourcing, marketing, licensing, and distributing branded footwear, apparel, and accessories. The company's segment includes Active Group; Work Group; Corporate and Other. It generates maximum revenue from the Active Group segment. Active Group segment consists of Merrell footwear and apparel, Saucony footwear and apparel, Sweaty Betty activewear, and Chaco footwear.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.